TUB-040
- Generic Name
- TUB-040
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Tubulis GmbH
- Target Recruit Count
- 100
- Registration Number
- NCT06303505
- Locations
- 🇩🇪
Charité Universitätsmedizin Berlin, Berlin, Germany
🇪🇸NEXT Oncology Madrid, Madrid, Spain
🇬🇧Guy's Hospital, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath